Grant Private Wealth Management Inc Has $410,000 Stock Holdings in Johnson & Johnson $JNJ

Grant Private Wealth Management Inc reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 93.1% in the 3rd quarter, Holdings Channel reports. The firm owned 2,209 shares of the company’s stock after selling 29,872 shares during the period. Grant Private Wealth Management Inc’s holdings in Johnson & Johnson were worth $410,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the business. Evolution Wealth Management Inc. bought a new stake in shares of Johnson & Johnson during the 2nd quarter worth $27,000. Semmax Financial Advisors Inc. raised its stake in Johnson & Johnson by 55.0% during the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after acquiring an additional 72 shares in the last quarter. GFG Capital LLC bought a new position in shares of Johnson & Johnson in the second quarter worth about $35,000. 1248 Management LLC acquired a new stake in shares of Johnson & Johnson in the 1st quarter valued at approximately $48,000. Finally, Vermillion & White Wealth Management Group LLC grew its holdings in shares of Johnson & Johnson by 66.4% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 376 shares of the company’s stock valued at $57,000 after purchasing an additional 150 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Raymond James Financial increased their price objective on shares of Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a research note on Wednesday, October 15th. Royal Bank Of Canada set a $240.00 price target on Johnson & Johnson in a research note on Wednesday. HSBC restated a “buy” rating and set a $240.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, December 10th. The Goldman Sachs Group increased their target price on Johnson & Johnson from $186.00 to $212.00 and gave the company a “buy” rating in a research report on Thursday, October 9th. Finally, Wells Fargo & Company boosted their price target on Johnson & Johnson from $212.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, December 12th. Four research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $208.85.

Johnson & Johnson Trading Up 0.6%

Shares of JNJ stock opened at $210.50 on Thursday. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $215.18. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The stock has a market cap of $507.14 billion, a price-to-earnings ratio of 20.32, a PEG ratio of 2.27 and a beta of 0.36. The stock has a 50-day moving average of $197.44 and a 200-day moving average of $178.46.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The company had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. On average, equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th were given a dividend of $1.30 per share. The ex-dividend date was Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.5%. Johnson & Johnson’s dividend payout ratio is 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.